Oculis Holding AG (OCS) FY 2025 Conference May 20, 2025 09:30 AM ET Speaker0 For this session, we'll have a presentation by Oculus. Oculus is a clinical stage ophthalmology company with a pipeline of candidates targeting diabetic macular edema, dry eye disease and acute optic neuritis. Presenting for the company is Ms. Silva Chin, Chief Financial Officer of Oculus. Speaker1 Thank you. Good morning, everyone. Thank you for your patience, and thank you, Yi, for the introduction. Thanks to H. C. Ringwright for ...

案例：不法分子常常编造"天上掉馅饼"的谎言，利用最新高科技理念虚假包装成投资项目，承诺保本且 有高收益，诱导投资者参与。在投资初期，他们信守承诺，按时足额兑付本息，可一旦资金积累到一定 程度，便会卷款潜逃，让投资者血本无归。 防范要点：在投资理财时，投资者应谨记"天上不会掉馅饼，高息保本是陷阱"，高收益往往伴随着高风 险。遇到宣传各种夸张的、具有诱惑性收益的投资产品，投资者应保持冷静理性，警惕"非法集资"的金 融诈骗陷阱，莫被高额回报冲昏头脑。正规的投资理财产品均会充分提示风险，充分披露产品的风险评 级、费用、投资范围、发行托管机构等信息，并要求匹配投资者的风险承受能力，不会承诺保证本金、 保证收益。 "专家内幕"赚大钱？小心投资杀猪盘！ 风险提示：理财非存款，产品有风险，投资须谨慎。 案例：一些不法分子伪装成投资专家，以"内幕消息""经验丰富""AI投资""专家荐股"等为噱头设立钓鱼 群，诱导投资者入群。群内"高手"热聊，展示历史投资高收益，宣传过往精准买卖点，在骗取投资者信 任后，诱骗投资者购买特定投资产品。随着受害者逐步放下戒备不断增加投资后，不法分子便会卷款消 失。 今年5月15日是第七个"全国投资者 ...

Core Viewpoint - Acadia Pharmaceuticals' shares increased by 26.5% following a favorable ruling from the U.S. District Court regarding the patent for its lead drug, Nuplazid, which protects the company from generic competition until 2038 [1][3]. Company Performance - Nuplazid is the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis in the U.S. [2] - In Q1 2025, Nuplazid generated $159.7 million in revenue, marking a 23% year-over-year increase driven by volume growth [3]. - Year-to-date, Acadia's shares have risen by 21.3%, contrasting with a 6.9% decline in the industry [4]. Product Portfolio - Acadia's other marketed drug, Daybue, approved for treating Rett syndrome, generated $84.6 million in revenue in Q1 2025, an 11% increase year-over-year [5]. - Daybue reached a record high of 954 unique patients receiving shipments in Q1 2025 [7]. Pipeline Developments - Acadia is awaiting EU regulatory approval for trofinetide to treat Rett syndrome, expected in Q1 2026 [8]. - The company anticipates top-line results from the phase III COMPASS PWS study of ACP-101 for Prader-Willi Syndrome in early Q4 2025, with plans to submit a regulatory application to the FDA in Q1 2026 [9]. - Enrollment for the phase II RADIANT study of ACP-204 for Alzheimer's disease psychosis is expected to be completed in Q1 2026, with top-line data anticipated in mid-2026 [10]. - Acadia and Saniona have completed the phase I study of ACP-711, which showed a strong safety profile, and are focusing on essential tremor as the lead indication [11][12].

Core Viewpoint - Scienture Holdings, Inc. has announced the FDA listing of two patents for its product Arbli, a novel oral liquid formulation of losartan, which is expected to enhance its market position and provide statutory exclusivity under the Hatch-Waxman Act [1][2][6]. Company Overview - Scienture Holdings, Inc. is a holding company focused on developing and distributing specialty pharmaceutical products that address unmet market needs [1][13]. - The company operates through its subsidiary, Scienture, LLC, which is dedicated to bringing unique specialty products to market [13]. Product Details - Arbli is the first FDA-approved ready-to-use oral liquid formulation of losartan, designed for patients over 6 years old, and is indicated for the treatment of hypertension and related conditions [3][4][8]. - The product is available in a 165 mL bottle with a peppermint flavor, has a shelf life of 18 months at room temperature, and does not require refrigeration [7]. Market Position - The patents for Arbli cover stable liquid formulations of losartan and methods of use, reinforcing Scienture's intellectual property position [2]. - Losartan is classified as an angiotensin receptor blocker (ARB) and is one of the most prescribed medications for hypertension, with annual sales of approximately $276 million and a prescription volume of 69 million in the U.S. market as of March 2025 [5]. Regulatory Milestone - The listing of Arbli in the FDA's Orange Book is considered a significant regulatory achievement for Scienture, validating its development efforts and enhancing its commercial pathway in the U.S. market [6][2].

投资者一旦参与，财富往往会被无情吞噬。为保护投资者合法权益，提高风险意识和识别能力，自 觉远离和抵制非法证券期货投资，小编今日和大家简单介绍4种识别非法证券期货陷阱的方法。 近年来非法证券期货活动手段不断翻新、隐蔽性越来越强，不法分子编造美好"钱景"，设定多种套 路敛财诈骗，诱导投资者坠入陷阱。 如何识别非法证券期货陷阱？ 1.看业务资质 4、看互联网址 （www.csrc.gov.cn）查询行政许可信息栏目，同时还可以登录上海证券交易所 （www.sse.com.cn）、深圳证券交易所（www.szse.cn）网站查询新股发行的具体信息；如果想 要知道一家公司或人员是否具备证券期货业务资格，可以登录中国证监会网站或中国证券业协会 （www.sac.net.cn）和中国期货业协会（www.cfachina.org）网站进行查询。 另外，全国中小企业股份转让系统有限责任公司也是经国务院批准的全国性证券交易场所，投资者 可以登录其网站（www.neeq.cc）查询具有主办券商业务资格的证券公司和挂牌公司有关信息。 2.看营销方式 开展证券期货业务活动，要遵守证券期货法律法规有关投资者适当性管理的要求，合法的证券期 ...

为深入贯彻落实投资者保护理念，陕西证券期货业协会于5月15日全国投资者保护日之际，联合西部证券、开源证券、中邮证券、西部期货、长安期货、迈 科期货六家机构，在西安地铁3号线启动为期一个月的"心系投资者，携手共行动"主题宣传活动。本次活动通过地铁车厢沉浸式的视觉化投教场景，将专业 金融知识转化为通俗易懂的公众语言，日均触达十万级客流，为市民打造"移动金融知识课堂"。 多主题联动，构建投教立体网络 活动以6节主题车厢为载体，形成差异化内容矩阵。西部证券车厢聚焦"基础投资服务"，通过中国境内三大证券交易所介绍、证券知识图解及反洗钱专栏， 帮助乘客厘清投资逻辑；开源证券车厢围绕"诉千年古都余韵，守投教为民信言"，将秦风唐韵文化融入金融教育肌理，借助"唐风小人"形象，构建传统与现 代交融的投教新范式；西部期货车厢以"期货知识科普"为核心，通过期货与现货对比表、防诈口诀顺口溜等内容，破解公众对衍生品市场的认知误区；长安 期货重点解析"防范非法证券期货活动六要六不要"，以案例警示强化理性投资意识；迈科期货以"风险防控"为主线，通过"高收益伴随高风险""警惕非法金 融陷阱"等警示标语，筑牢市民财产安全防线；中邮证券则以"投资 ...

l P 10 华夏时报（www.chinatimes.net.cn）记者 卢梦雪 见习记者 张萌 北京报道 近年来，随着我国财富管理行业的迅速发展，投资者的资产配置渠道更加多元化，风险也变得更加隐蔽和复杂， 投资者权益保护问题成为社会关注的焦点。 公开数据显示，A股市场总市值已突破百万亿元，截至去年年底，我国公募基金规模超32万亿元，私募基金规模 接近20万亿元。然而，在市场快速发展的背后，中小投资者的权益保护问题依然突出。无论是私募基金、资管计 划、信托产品，还是数字资产、境外投资等新兴领域，投资者频繁遭遇侵权和欺诈，且在合法权益受损后，往往 缺乏有效的维权途径。 中小投资者作为市场的流动性提供者和风险承担者，其权益保障水平直接影响市场资源配置效率和稳定性。 然而，信息不对称问题长期存在。 据新华网编委、上市公司研究院常务副院长邱小敏介绍，截至5月14日，A股市场总市值已达到102万亿元；截至 2024年年底，我国公募基金总规模已超过32万亿元，私募基金规模接近20万亿元。若将视野放大至更广义的金融 市场，银行理财在2024年的存续总额已达到近30万亿元的总体量，加上保险、信托、期货等投资，总规模大约在 3 ...

Ideal Power (IPWR) Q1 2025 Earnings Call May 15, 2025 10:00 AM ET Company Participants Jeff Christensen - Investor RelationsR. Daniel Brdar - President, CEO & DirectorTim Burns - Chief Financial OfficerCasey Ryan - Director - Institutional Research Operator Good morning, ladies and gentlemen, and welcome to the Ideal Power First Quarter twenty twenty five Results Conference Call. All participants are on a listen only mode. At the end of management's remarks, there will be a question and answer session. Inve ...

Ideal Power (IPWR) Q1 2025 Earnings Call May 15, 2025 10:00 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to the Ideal Power First Quarter twenty twenty five Results Conference Call. All participants are on a listen only mode. At the end of management's remarks, there will be a question and answer session. Investors can submit their questions anytime within the meeting webcast by typing them into the Q and A button on the left side of your viewing screen. Analysts who publish research may a ...

21世纪经济报道记者崔文静 北京报道 5月15日，一年一度的全国投资者保护宣传日到来。 当日，一份司法保障资本市场高质量发展的纲领性文件《关于严格公正执法司法 服务保障资本市场高 质量发展的指导意见》（下称《指导意见》）出台，该文件由最高人民法院和证监会联合发布，旨在强 化司法与行政协同，全方位助推资本市场高质量发展。 《指导意见》从总体要求、投资者保护、市场参与人规范、司法行政协同及组织实施保障等五个方面， 提出了严格公正执法司法、保障资本市场改革发展的23条意见。其中，多个亮点值得重点关注。 首先，投资者保护被视为首要内容，围绕于此，一系列投资者利好法规被提出。最值得关注之处在于， 对于实践中时有出现的问题——券商、银行等金融机构工作人员向客户推荐相关产品时，未尽适当性管 理义务，投资者蒙受损失。按照《指导意见》要求，此种情况下，相关机构需要向投资者进行赔偿。 其次，近年来反复提及的财务造假，同样是《指导意见》的严惩对象。其明确，依法严厉打击欺诈发 行、违规信息披露等财务造假违法犯罪。对于配合财务造假的第三方，此前业内人士认为惩处力度不 足，此番《指导意见》明确，将对其依法追究刑事责任。 再者，对于让不少 ...